Not for sure - I've read it could be as low as $USD 500 million a year and as high as $USD 2 billion.
I don't think breakthrough cancer pain was selected for its total addressable market, however.
If I've got this right, cancer pain treatment is the easiest pathway to get FDA approval. IRX 211 only needs to show a slight reduction in cancer pain scores to demonstrate efficacy. In other words, we have an exceptionally high chance of satisfying the FDA's threshold.
Breakthrough cancer pain is also the same reason why we have the potential to reduce or even eliminate the need for a phase 3.
FDA approval for one indication would then enable the company to leverage the data to branch out into other ailments/markets such as Complex Regional Pain Syndrome. There are a few other irons in the fire, too.
There's also the even much greater 'off label' prescription potential. GLTAH
Add to My Watchlist
What is My Watchlist?
